CLEARONE INC — Form S-1/A
Filed September 4, 2026 · analyzed by the Registration Agent
S-1/A
— Neutral
significance 78/100
What the filing says
ClearOne Inc (market cap ~$5.1M) filed an amended S-1 registration for a best-efforts public offering of 2.86–4.29M units at $3.50/unit ($10–15M gross proceeds). Each unit contains one common share and one warrant (exercise price $10, 6-month expiry). Net proceeds ($9.05–13.75M after 6% placement agent fees) will fund the pending merger with Cortigent (a pre-revenue neurostimulation medical device company) via acquisition by Vivani Medical. Vivani shareholders receive 12.5M consideration shares; First Finance Ltd holds 61.34% and will invest $1M in the offering. The merger conditions include $50k minimum cash post-closing and stockholder/Nasdaq approvals already obtained (Aug 25, 2026).
Why this rating
Material capital raise (~2× current market cap) + transformational merger with pre-revenue medical device company. Significant dilution (80%+ share increase if max units sold), extreme execution risk (unproven neurostimulation products, clinical trial dependence, going-concern doubt). High relative to company size but merger is speculative, not imminent revenue.
Price action (we called it neutral)
before filing · preread $5.25 ▲ 3.14% | at our read · unknown $5.09 | +10 min · unknown $5.09 ▲ 0.00% | +30 min · unknown $5.09 ▲ 0.00% | +1 hr · unknown $5.09 ▲ 0.00% | +4 hrs pending |
The stock had already moved -3.05% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.